Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2000
08/16/2000EP1027047A1 Eprosartan arginyl charge-neutralization-complex and a process for its production and formulation
08/16/2000EP1027036A2 Taste masked formulations
08/16/2000EP1027027A2 Therapeutic method
08/16/2000EP1027016A1 Methods and pharmaceutical compositions for the closure of retinal breaks
08/16/2000EP1027011A1 Administration of active agents, including 5-ht receptor agonists and antagonists, to treat premature ejaculation
08/16/2000EP1026950A1 Treatment of schizophrenia with ampakines and neuroleptics
08/16/2000EP0799045B1 Treatment of hyperexcited nerve cell functions
08/16/2000CN1263560A Methods for diagnosis and treating cancers, and methods for identifying pathogenic markers in sample of normal cells
08/16/2000CN1263471A Pharmaceutical composition having enhanced antitumor activity and/or reduced side effects, containing antitumor agent and hydroxamic acid derivative
08/16/2000CN1263467A Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor
08/16/2000CN1263465A Treatment and prevention of cardiac disorders using selective 5-hydroxytryptamine re-uptake inhibitors
08/16/2000CN1263454A Device and method for treatment of dysmenorrhea
08/15/2000US6103874 Human KDEL receptor
08/15/2000US6103869 Isolated polypeptide with a mutation at amino acid 464, 465, and/or 467 resulting in dominant negative inhibition of transforming growth factor-beta signaling; therapy and diagnosis of related diseases
08/15/2000US6103771 Method of treating neuroma pain
08/15/2000US6103765 Methods for treating male erectile dysfunction
08/15/2000US6103756 An effective amounts of vitamin a,b,c, magnesium, selenium, extract of bilberry, lutein and lycopene extracts, l-taurine, lipoic acid/a-/, quercetin, rutin and citrus flavonoids useful for prevention of age related vision defects
08/15/2000US6103742 Administering to said patient a therapeutically effective amount of an insulin sensitivity enhancer in combination with a statin compound to treat diabetes
08/15/2000US6103735 Composition and method for treating allergic diseases
08/15/2000US6103722 Ischemic preconditioning
08/15/2000US6103713 Therapeutic treatment for autoimmune diseases
08/15/2000US6103712 Selective inhibitors of the beta isozyme of protein kinase c inhibits pulmonary vascular permeability, bronchial smooth muscle contractility, and airway hyperactivity, e.g. bisindolylmaleimides
08/15/2000US6103711 Inhibitors of interleukin-1β converting enzyme
08/15/2000US6103710 Glucocorticoid response elements
08/15/2000US6103705 Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
08/15/2000US6103704 Topically administering a therapeutically effective dosage of a formulation which comprises hyaluronic acid and an antiinflammatory or anticarcinogenic agent; treatment of diseases and conditions of the skin and exposed tissue
08/15/2000US6103701 Method for enhancing hematopoiesis with acyl deoxyribonucleosides
08/15/2000US6103694 Method of decreasing radiation of radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
08/15/2000US6103692 Administering to said mammal, or contacting said cells with, a compound which inhibits lipid-dependent direct binding of a non-effector loop domain of ras with a raf zinc finger domain
08/15/2000US6103507 Protein used to raise an immunological response against a bacteria; bactericides
08/15/2000US6103494 Nucleotide sequences which code protein associated with immmune response; for the detection of flea allergy dermatitis; for the detection of modulators of immune response
08/15/2000US6103491 Methods and compositions for identifying morphogen analogs
08/15/2000US6103258 Administering a therapeutic dose of an opioid analgesic agonist and an amount of nalmefene to enhance the effects of dopamine-increasing opioid receptors and reduce the effects of dopamine-decreasing opioid receptors.
08/15/2000US6103234 Antibody to an inflammatory cytokine, said inflammatory cytokine comprising a mature macrophage inflammatory protein -2 (mmip-2)
08/15/2000US6103230 Methods for promoting wound healing and treating transplant-associated vasculopathy
08/15/2000CA1341087C Medicaments including hyaluronic acid as a drug delivery system
08/10/2000WO2000046391A2 Genes displaying enhanced expression during cellular senescence and terminal cell differentiation and uses thereof
08/10/2000WO2000046248A1 Use of agonists or antagonists of mip-3a in therapy
08/10/2000WO2000046246A1 Alpha-2-macroglobulin therapies and drug screening methods for alzheimer's disease
08/10/2000WO2000046215A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
08/10/2000WO2000045852A1 Method of treating cancer by restoration of pp32 function
08/10/2000WO2000045851A2 Preparation for the prevention and/or treatment of a tissue change of mesenchymal origin
08/10/2000WO2000045847A1 Novel mucosal delivery system
08/10/2000WO2000045846A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
08/10/2000WO2000045845A2 Liposome composition and method for administration of a radiosensitizer
08/10/2000WO2000045844A1 Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
08/10/2000WO2000045837A1 Novel use within transplantation surgery
08/10/2000WO2000045836A1 Uses of thank, a tnf homologue that activates apoptosis
08/10/2000WO2000045835A1 Vascular endothelial growth factor-2
08/10/2000WO2000045832A2 Regulation of anaesthesia
08/10/2000WO2000045822A1 Phosphocholine surfactants and their use
08/10/2000WO2000045818A1 Use of 3-hydroxy-3-methylglutaryl coenzym a reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy
08/10/2000WO2000045817A1 Drug combinations comprising (e) -7 - [4 -(4 -fluorophenyl) -6 - isopropyl -2 - [methyl (methylsulfonyl) amino] pyrimidin -5 -yl] (3r,5s) -3,5 - dihydroxyhept -6 - enoic acid and an inhibitor, inducer or substrate of p450 isoenzyme 3a4
08/10/2000WO2000045815A1 Methods for alleviating discomfort of a hot flash and compositions therefor
08/10/2000WO2000045809A1 L-arginine based formulations for treating diseases and methods of using same
08/10/2000WO2000045800A2 Immunosurpressive effects of pteridine derivatives
08/10/2000WO2000045792A1 Hydrogel particle formulations
08/10/2000WO2000045791A2 Method for controlling liposome size
08/10/2000WO2000045786A1 Cholesterol sulfate compositions for enhancement of stratum corneum function
08/10/2000WO2000045770A2 Compressed lecithin preparations
08/10/2000WO2000045634A1 Inositol derivatives for inhibiting superoxide anion production
08/10/2000WO2000029008A3 Hiv-specific t-cell induction
08/10/2000WO2000027372A8 Pharmaceutical preparations for external use containing non-steroidal anti-inflammatory and analgesic agents
08/10/2000WO2000024911A3 Human phospholipases
08/10/2000WO2000013706A8 Methods for detecting, preventing, and treating renal disorders by modulating, regulating, and inhibiting connective tissue growth factor
08/10/2000WO2000010588A9 Epidermal growth factor receptor antagonists for treating hypersecretion of mucus in the lungs
08/10/2000WO2000010545A3 Use of substance p antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of nk-1 receptor antagonists for the treatment of chronic fatigue syndrome
08/10/2000WO1999066072A3 Methods for treating a neurological disease by determining bche genotype
08/10/2000WO1999063936A9 Novel therapeutic agents that modulate endothelin receptors
08/10/2000DE19904801A1 Agent containing urea, sulfur and Calendula extract, useful for topical treatment of skin disorders, especially neurodermatitis
08/10/2000DE19903398A1 Verwendung von Thiadiazolderivaten zur prophylaktischen und therapeutischen Behandlung von Infektionen The use of thiadiazole derivatives for the prophylactic and therapeutic treatment of infections
08/10/2000DE19903087A1 Behandlung von erektilen Dysfunktionen mit C-Typ Natriuretischem Polypeptid (CNP) als Monotherapie oder in Kombination mit Phosphodiesterasehemmern Treatment of erectile dysfunction with C-type natriuretic polypeptide (CNP) as monotherapy or in combination with phosphodiesterase inhibitors
08/10/2000CA2361838A1 Method of treating cancer by restoration of pp32 function
08/10/2000CA2361615A1 The use of vascular endothelial growth factor 2 antagonist in the treatment of an injury to or disorder of an eye
08/10/2000CA2361575A1 L-arginine based formulations for treating diseases and methods of using same
08/10/2000CA2361561A1 Immunosurpressive effects of pteridine derivatives
08/10/2000CA2361555A1 Hydrogel particle formulations
08/10/2000CA2361551A1 Method for controlling liposome size
08/10/2000CA2361539A1 Compressed lecithin preparations
08/10/2000CA2361437A1 Pharmaceutical compositions containing nicotine or a ligand of nicotine receptors and a monamine oxydase inhibitor and their use for treating tobacco withdrawal symptoms
08/10/2000CA2361066A1 Inositol derivatives for inhibiting superoxide anion production
08/10/2000CA2361046A1 Methods for alleviating discomfort of a hot flash and compositions therefor
08/10/2000CA2360942A1 Preparations for preventing and/or treating a tissue change of mesenchymal origin
08/10/2000CA2360941A1 Liposome composition and method for administration of a radiosensitizer
08/10/2000CA2360124A1 Regulation of anaesthesia
08/10/2000CA2358855A1 Benzazepine derivatives as alpha-v integrin receptor antagonists
08/09/2000EP1026251A2 Transgenic animals expressing human P25
08/09/2000EP1025840A2 Oral drug compositions and methods
08/09/2000EP1025238A2 Death associated kinase containing ankyrin repeats (dakar)
08/09/2000EP1025237A2 Human checkpoint kinase, hcds1, compositions and methods
08/09/2000EP1025236A2 Human checkpoint kinase, hcds1, compositions and methods
08/09/2000EP1025228A1 Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
08/09/2000EP1025227A2 Human toll homologues
08/09/2000EP1025223A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
08/09/2000EP1025216A1 Transgenic animal models for cardiac hypertrophy and uses thereof
08/09/2000EP1024836A1 Method of delivering genes to antigen presenting cells of the skin
08/09/2000EP1024835A1 J-chain and analogues as epithelial cell targeting conjugates
08/09/2000EP1024831A2 Application of tnf antagonists as medicaments for treating septic diseases
08/09/2000EP1024828A1 NOVEL pheS (BETA)
08/09/2000EP1024823A1 Prevention and treatment of adhesion formation
1 ... 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 ... 1151